Filtered By:
Source: Molecular Immunology
Condition: Diabetes Type 2
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Anagliptin ameliorates high glucose- induced endothelial dysfunction via suppression of NLRP3 inflammasome activation mediated by SIRT1
Publication date: March 2019Source: Molecular Immunology, Volume 107Author(s): Tiechao Jiang, Dongli Jiang, Lirong Zhang, Mei Ding, Hui ZhouAbstractHigh glucose- induced endothelial dysregulation has been recognized as an initiation of vascular complications in Type 2 diabetes mellitus (T2DM). Anagliptin is a novel licensed dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of T2DM. The effects of anagliptin in high glucose- induced endothelial dysfunction are less reported. In the current study, we found that treatment with anagliptin prevented high glucose- induced reduction of cell viability and increase in LDH ...
Source: Molecular Immunology - January 18, 2019 Category: Allergy & Immunology Source Type: research
